Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE 0.1%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $272713 | $2M | $79M | $77M | $121M | $907M | $587M | — | — |
| Enterprise Value | $-5136449287 | $-5134476771 | $83M | $72M | $121M | $883M | $578M | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 15.46 | 13.17 | 20.12 | 116.06 | 61.45 | — | — |
| P/B Ratio | 0.00 | 0.00 | — | 6.15 | 7.22 | 25.50 | 33.63 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 16.18 | 12.30 | 20.20 | 113.06 | 60.48 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 76.3% | 72.0% | 61.8% | 79.5% | 57.7% | 18.4% | 25.4% |
| Operating Margin | — | — | -345.8% | -233.9% | -332.4% | -231.1% | -180.8% | -124.0% | -54.4% |
| Net Profit Margin | — | — | -280.1% | -140.2% | -334.4% | -115.0% | -215.3% | -208.7% | -231.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 0.1% | 0.1% | -571.3% | -55.9% | -76.7% | -33.9% | -161.5% | -1025.9% | — |
| ROA | 0.1% | 0.1% | -64.5% | -24.7% | -40.2% | -13.1% | -32.1% | -51.9% | -48.5% |
| ROIC | — | — | -730.9% | -83.1% | -102.1% | -133.7% | -93.4% | -46.5% | -13.4% |
| ROCE | -0.3% | -0.3% | -226.2% | -56.3% | -64.5% | -56.1% | -76.4% | -84.7% | -27.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.66 | 0.59 | 0.01 | 0.45 | 1.71 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 113.79 |
| Net Debt / Equity | — | -1.79 | — | -0.41 | 0.03 | -0.66 | -0.53 | 1.45 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | 107.05 |
| Debt / FCF | — | — | — | — | — | — | — | 4.71 | 7.22 |
| Interest Coverage | — | — | -24.53 | -14.23 | -32.62 | -23.38 | -6.22 | -1.39 | — |
Net cash position: cash ($5.1B) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.25 | 2.25 | 0.40 | 1.89 | 2.08 | 0.99 | 0.62 | 0.29 | 0.41 |
| Quick Ratio | 2.25 | 2.25 | 0.24 | 1.74 | 1.82 | 0.97 | 0.60 | 0.24 | 0.24 |
| Cash Ratio | 2.24 | 2.24 | 0.21 | 1.24 | 1.33 | 0.77 | 0.41 | 0.05 | 0.07 |
| Asset Turnover | — | — | 0.48 | 0.17 | 0.18 | 0.12 | 0.14 | 0.27 | 0.21 |
| Inventory Turnover | — | — | 0.40 | 1.01 | 1.26 | 3.08 | 5.32 | 5.77 | 1.61 |
| Days Sales Outstanding | — | — | 29.71 | 139.56 | 128.54 | 143.19 | 196.75 | 90.17 | 91.23 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 100.0% | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 100.0% | 15.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 100.0% | 15.2% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $281M | $8M | $2M | $2M | $1M | $534068 | $246003 | $100000 |
Binary Regulatory Failure Risk
As reported in historical financial statements, PTPI's ROIC has trended deeply into negative territory, reaching -145.5% in 2023Q4, which suggests that the company is currently destroying shareholder capital rather than compounding it while it attempts to navigate the high-cost FDA nonprescription drug product regulatory pathway.
The extreme volatility in ROIC and ROE metrics reflects a business model that has abandoned commercial operations in favor of speculative regulatory milestones. Investors should interpret these negative returns as a direct consequence of high fixed-cost R&D spending without any offsetting revenue generation to support the capital base.
Based on the provided quarterly data, the company's cash conversion cycle reached an elevated 519 days in 2024Q4, which indicates significant operational friction and an inability to efficiently manage inventory or receivables during the transition away from its legacy prescription-based business model toward an OTC-focused strategy.
The erratic nature of the CCC, including negative values in 2023Q4, suggests that the company's working capital management is currently dictated by accounting adjustments rather than operational throughput. This lack of efficiency highlights the difficulty of maintaining a lean cost structure while the firm remains in a dormant, pre-revenue state.
According to recent quarterly filings, the current ratio has fluctuated wildly between 0.40 and 2.51, suggesting that the company's ability to meet short-term obligations is entirely dependent on external financing rather than internal cash generation, leaving the balance sheet in a highly vulnerable position under stress.
The inconsistency in liquidity ratios implies that the company may face recurring funding gaps as it burns through cash to support clinical studies. Analysts should monitor these ratios closely, as any further decline in the current ratio could necessitate dilutive capital raises to maintain basic regulatory compliance.
As indicated by the company's current financial profile, the use of P/E or EV/EBITDA ratios is fundamentally inappropriate for PTPI, as these metrics obscure the reality that the firm is currently a pre-revenue regulatory option rather than a functioning commercial entity with predictable earnings power.
Investors often misapply earnings-based multiples to this business model, which ignores the binary nature of the FDA's ACNU pathway. Instead of traditional valuation, the company's worth should be assessed based on the intrinsic value of its proprietary 'Actual Use Study' data and the probability-weighted success of its OTC transition.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PTPI stock.
Petros Pharmaceuticals, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Petros Pharmaceuticals, Inc.'s return on equity (ROE) is 0.1%. The historical average is -65.6%.
Based on historical data, Petros Pharmaceuticals, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.